Methods of treating cancer using anti-pd-l1 antibodies and antiandrogens
US-2019309071-A1 · Oct 10, 2019 · US
Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodies
US11767362B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-11767362-B1 |
| Application number | US-201716084346-A |
| Country | US |
| Kind code | B1 |
| Filing date | Mar 14, 2017 |
| Priority date | Mar 15, 2016 |
| Publication date | Sep 26, 2023 |
| Grant date | Sep 26, 2023 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating or delaying progression of cancer in an individual, comprising administering a therapeutically effective amount of an anti-GPC3 antibody to the individual, wherein the individual is also being administered atezolizumab, wherein the anti-GPC3 antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:42, HVR-H2 sequence of SEQ ID NO: 43, and HVR-H3 sequence of SEQ ID NO: 44; and a light chain comprising HVR-L1 sequence of SEQ ID NO: 45, HVR-L2 sequence of SEQ ID NO: 46, and HVR-L3 sequence of SEQ ID NO: 47, and wherein the cancer is liver cancer. 2. The method according to claim 1 wherein the anti-GPC3 antibody is a humanized antibody. 3. The method according to claim 2 , wherein the anti-GPC3 antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:50 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:52. 4. The method according to claim 1 , wherein the cancer is selected from the group consisting of liver cancer, breast cancer, lung cancer, ovarian cancer, gastric cancer, bladder cancer, pancreatic cancer, endometrial cancer, colon cancer, kidney cancer, esophageal cancer and prostate cancer. 5. A method for treating or delaying progression of cancer in an individual, comprising administering to the individual a therapeutically effective amount of an anti-GPC3 antibody, and administering a therapeutically effective amount of atezolizumab, wherein the anti-GPC3 antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:42, HVR-H2 sequence of SEQ ID NO: 43, and HVR-H3 sequence of SEQ ID NO: 44; and a light chain comprising HVR-L1 sequence of SEQ ID NO: 45, HVR-L2 sequence of SEQ ID NO: 46, and HVR-L3 sequence of SEQ ID NO: 47, and wherein the cancer is liver cancer. 6. A method for treating or delaying progression of cancer in an individual, comprising administering a therapeutically effective amount of atezolizumab to the individual, wherein the individual is also being administered a therapeutically effective amount of an anti-GPC3 antibody, wherein the anti-GPC3 antibody comprises a heavy chain comprising HVR-H1 sequence of SEQ ID NO:42, HVR-H2 sequence of SEQ ID NO: 43, and HVR-H3 sequence of SEQ ID NO: 44; and a light chain comprising HVR-L1 sequence of SEQ ID NO: 45, HVR-L2 sequence of SEQ ID NO: 46, and HVR-L3 sequence of SEQ ID NO: 47, and wherein the cancer is liver cancer. 7. The method according to claim 5 wherein the anti-GPC3 antibody is a humanized antibody. 8. The method according to claim 6 wherein the anti-GPC3 antibody is a humanized antibody.
Assignees
Inventors
Classifications
- C07K16/2827Primary
against B7 molecules, e.g. CD80, CD86 · CPC title
Antineoplastic agents · CPC title
- C07K16/303Primary
Liver or Pancreas · CPC title
containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered · CPC title
F(ab')2 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11767362B1 cover?
- The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a …
- Who is the assignee on this patent?
- Chugai Pharmaceutical Co Ltd, Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2827. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 6 related publications on this page (citations in our corpus or others sharing the same primary CPC).